A new simple dosing regimen to treat chemotherapy-induced nausea and vomiting (CINV) has been launched in the UK.
MSD’s Ivemend (fosaprepitant dimeglumine) 150 mg is indicated in combination with other antiemetics for the prevention of acute and delayed nausea and vomiting due to highly or moderately emetogenic cisplatin-based cancer chemotherapy.
The 150 mg dosing regimen means that just one treatment is needed on day one of chemotherapy, with no need for further treatments on days two and three.
Approximately 70 – 80% of people treated for cancer experience nausea and vomiting, which can lead to dehydration, fatigue, loss of appetite and weight loss.
“Nausea and/or vomiting affect many people receiving chemotherapy to varying degrees and can significantly affect quality of life. It is commonly underestimated by health professionals and under reported by patients,” said Elaine Lennan, Consultant Cancer Nurse, Southampton University Hospitals Trust.
“Availability of this new option will offer health professionals flexibility in personalising anti-sickness regimens and help them focus on preventing rather than treating CINV. This is a welcome addition.”